The global respiratory infections antibiotics market reached $10.83 billion in 2026, but mounting evidence suggests a troubling portion of those prescriptions are medically unnecessary. At the heart of this disconnect lies a persistent gap between what clinicians suspect and what diagnostic tools can prove – and the consequences extend far beyond wasted medication.
87% of Respiratory Infections Are Viral
A comprehensive Croatian study analyzing over 15,000 respiratory infection cases throughout 2024 has confirmed what antimicrobial stewardship advocates have warned about for years: the vast majority of acute respiratory infections presenting in primary care are viral, not bacterial. The study found that 87% of detected pathogens were viruses, with rhinovirus and enterovirus accounting for nearly 40% of all positive results, followed by influenza A at 14.5% and SARS-CoV-2 at 9.5%.
The implications for antibiotic prescribing are stark. Despite this viral predominance, physicians continue to prescribe antibiotics empirically for respiratory symptoms, often without confirming a bacterial infection. The study’s authors emphasize that the testing panels that distinguish viral from bacterial infections provide crucial clinical decision support that could prevent thousands of unnecessary antibiotic courses.
The Resistance Crisis Deepens
What makes this particularly urgent in 2026 is the parallel rise in antimicrobial resistance. Recent data from the All India Institute of Medical Sciences found resistance rates to common antibiotics like co-trimoxazole, ampicillin-sulbactam, and cefotaxime ranging from 67% to 80% in respiratory samples. The selective pressure from inappropriate antibiotic use is creating precisely the resistant strains that make treating genuine bacterial infections increasingly difficult.
The Croatian research employed multiplex PCR panels capable of simultaneously detecting 13 respiratory pathogens – eight viruses and five bacteria – from a single nasopharyngeal swab. This approach addresses a fundamental limitation of traditional diagnostic methods: the inability to quickly and accurately differentiate between viral and bacterial causes of similar symptoms.
Co-Infections Challenge Assumptions
Beyond individual pathogen detection, the study revealed that co-infections occurred in 17.4% of positive cases, with most involving multiple viruses rather than viral-bacterial combinations. This finding challenges the clinical assumption that severe or prolonged respiratory symptoms necessarily indicate a bacterial superinfection requiring antibiotics.
The seasonal patterns documented in the study also upend traditional assumptions about respiratory pathogen circulation. While influenza A and respiratory syncytial virus peaked in the first quarter as expected, SARS-CoV-2 showed its highest circulation during the summer months – 48% of all COVID cases occurred between July and September. This off-season viral activity complicates empirical treatment decisions even further, as clinicians can no longer rely on time of year to guide their diagnostic suspicions.
When Bacteria Actually Matter
Among the bacterial pathogens detected, Mycoplasma pneumoniae, Bordetella pertussis, and Chlamydia pneumoniae were most common, each requiring specific antibiotic regimens distinct from broad-spectrum agents typically prescribed for presumed bacterial respiratory infections. The study found these bacteria were particularly prevalent among school-aged children, suggesting that targeted testing in this demographic could significantly improve treatment appropriateness.
The public health dimension extends beyond resistance. Unnecessary antibiotic prescriptions carry direct patient risks, including Clostridioides difficile infection, allergic reactions, and microbiome disruption. A 2026 Nature Communications trial examining multiplex PCR in community-acquired pneumonia found that while rapid testing didn’t significantly reduce antibiotic days, it provided valuable data for understanding when antibiotics truly aren’t indicated.
The Cost-Benefit Calculation
Cost considerations complicate the stewardship equation. At approximately €25 per multiplex PCR test in the Croatian setting, systematic testing for all respiratory infections would represent a substantial upfront investment. However, this calculation doesn’t account for the downstream costs of antibiotic resistance, treatment failures, adverse drug events, or the societal burden of preventable resistant infections.
The study’s authors argue for a more nuanced approach: reserving multiplex testing for cases where antibiotic therapy is being seriously considered, particularly in high-risk groups, severe cases, or situations where clinical presentation alone cannot reliably distinguish viral from bacterial infection. This targeted strategy could capture much of the stewardship benefit while containing diagnostic costs.
What the Croatian data makes clear is that the current paradigm – empirical antibiotics for respiratory symptoms based on clinical judgment alone – systematically overestimates bacterial involvement. In a healthcare landscape increasingly shaped by antimicrobial resistance, that systematic error has consequences far beyond the individual patient encounter.
The technology exists to diagnose with precision. The question facing primary care systems in 2026 is whether the immediate cost of better diagnostics outweighs the long-term cost of resistance – and whether we’re willing to change prescribing patterns even when the answer is uncomfortable.